Malvern, PA, USA – November 2024 – Resolian, a leading global bioanalytical and analytical sciences partner supporting drug development and multi-regional clinical trials, has announced key leadership changes to drive its next chapter of growth. Rob Stachlewitz has been appointed as Chief Executive Officer (CEO), while current CEO Pat Bennett will transition to the role of Chief Business Officer and President of Scientific Affairs. Additionally, the board has appointed Honggang Bi as Chairman.
Honggang Bi, who brings over 30 years of experience with Pfizer, Covance, and Labcorp, expressed his enthusiasm for his new role: “It’s an honor to be appointed Chairman of Resolian. I am excited to work alongside Rob, Pat, the Ampersand and KKR teams, and our nearly 500 global employees. Resolian is an innovative, global, bioanalytical and analytical CRO, and I am confident in our ability to execute our clients’ therapeutic programs.”
Rob Stachlewitz joins Resolian from Charles River, where he served as Corporate Vice President and General Manager and oversaw their largest site. With 15 years of pharmaceutical R&D experience, including roles at Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble, Stachlewitz brings a wealth of knowledge in global operations. He will guide Resolian’s strategic growth, enhancing operational capabilities and expanding global presence. Honggang Bi commented on Rob’s appointment: “With Rob’s extensive background shepherding life science businesses on a global scale, we are confident that he will lead Resolian to new heights.”
Pat Bennett, who led Resolian through a transformative period, will focus on expanding service capabilities and strengthening client relationships in his new role as Chief Business Officer and President of Scientific Affairs. Bennett has over 30 years of experience in bioanalytical sciences and will oversee critical functions to enhance client collaboration across the organization.
Dave Patteson, Partner at Ampersand Capital Partners, emphasized the significance of the leadership team: “The combined leadership of Honggang, Rob, and Pat is unrivaled in the bioanalytical CRO industry. The Resolian team will provide industry-leading bioanalytical services to clients for drug development projects across all major geographies.”
About Resolian:
Resolian is a global research laboratory offering specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. With nearly 500 experts across the U.S., U.K., and Australia, Resolian delivers quality results that meet the highest standards of regulatory compliance throughout the drug development continuum.
Read Also : Cultivating Safe Spaces: The Strategic Role of L&D in Workplace Well-being
